MederiAI develops AI-powered solutions for drug discovery and development, focusing on accelerating the identification of novel therapeutic targets and optimizing drug candidates. Their platform leverages machine learning to analyze complex biological data, aiming to improve the efficiency and success rates of preclinical research.
Funding
Funding not disclosed
Founders
Product
Problem
Reviewing endoscopic pill footage for gastrointestinal (GI) diagnostics is a time-consuming process for healthcare professionals. Manual analysis can lead to delayed diagnoses and potential oversight of critical anomalies within the GI tract.
Solution
MederiAI offers an AI-powered platform designed to provide near real-time analysis of endoscopic pill footage, enabling quicker and more accurate diagnoses. The platform leverages AI and deep learning to automate video summarization, detect anomalies, and predict potential issues within the GI tract. By providing predictive insights and early warning notifications, MederiAI aims to enhance decision-making and improve patient care. The system also allows doctors to compare videos between visits, highlighting improvements or worsening conditions.
Target Audience
MederiAI targets healthcare professionals, specifically gastroenterologists and endoscopists, who utilize endoscopic pill cameras for GI diagnostics.
Features
- AI-driven anomaly detection and localization within the GI tract, including estimation of capsule location and density distribution per segment.
- Automatic generation of reports summarizing key findings and analyses.
- Early warning notifications via email or SMS for critical events such as blood detection or delayed colon arrival.
- Video comparison tool to highlight changes between patient visits.
- Cleanliness scale per segment, evaluating mucosa quality in each video frame.